| Market Cap | 8.83M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.46M | Forward P/E | -0.65 | EPS next Y | - | 50D Avg Chg | -13.00% |
| Sales | 3k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -63.00% |
| Recommedations | 3.00 | Quick Ratio | 11.60 | Shares Outstanding | 0.91M | 52W Low Chg | 15.00% |
| Insider Own | 45.47% | ROA | -172.63% | Shares Float | 700.06K | Beta | 1.09 |
| Inst Own | 3.52% | ROE | -368.99% | Shares Shorted/Prior | 19.39K/4.63K | Price | 0.59 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 86,603 | Target Price | - |
| Oper. Margin | -237,633.33% | Earnings Date | - | Volume | 16,144 | Change | 0.31% |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lazar David E. | 10% Owner 10% Owner | Jul 06 | Buy | 0.89 | 2,226,190 | 1,981,309 | 359,066 | 07/08/22 |